Compare · ILMN vs TWST
ILMN vs TWST
Side-by-side comparison of Illumina Inc. (ILMN) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ILMN focuses on Medical Specialities, while TWST focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ILMN is the larger of the two at $41.33B, about 3.2x TWST ($12.81B).
- Over the past year, ILMN is up 168.6% and TWST is up 500.4% - TWST leads by 331.8 points.
- TWST has been more active in the news (14 items in the past 4 weeks vs 3 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 17 for TWST).
- Company
- Illumina Inc.
- Twist Bioscience Corporation
- Price
- $266.61+0.30%
- $184.15-2.06%
- Market cap
- $41.33B
- $12.81B
- 1M return
- +24.96%
- +40.57%
- 1Y return
- +168.58%
- +500.42%
- Industry
- Medical Specialities
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2018
- News (4w)
- 3
- 14
- Recent ratings
- 25
- 17
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest ILMN
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)
- UBS resumed coverage on Illumina with a new price target
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Director Meister Keith A. sold $57,199,201 worth of shares (263,560 units at $217.03) (SEC Form 4)
- The Market Just Told You Which Layer Of AI Biology It Is Paying For
- Director Meister Keith A. sold $85,241,664 worth of shares (375,941 units at $226.74) (SEC Form 4)
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
Latest TWST
- SEC Form 4 filed by Twist Bioscience Corporation
- Officer Cho Dennis sold $57,591 worth of shares (348 units at $165.49), decreasing direct ownership by 0.47% to 73,303 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Leproust Emily M. sold $279,183 worth of shares (1,687 units at $165.49), decreasing direct ownership by 0.27% to 618,902 units (SEC Form 4) (for tax liability)
- SVP of Human Resources Green Paula sold $48,654 worth of shares (294 units at $165.49), decreasing direct ownership by 0.25% to 116,720 units (SEC Form 4) (tax liability)
- Chief Executive Officer Leproust Emily M. exercised 208,708 shares at a strike of $20.21 and sold $56,330,724 worth of shares (356,546 units at $157.99) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 620,589 units (SEC Form 4)
- Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
- Officer Cho Dennis sold $50,521 worth of shares (412 units at $122.62), decreasing direct ownership by 0.56% to 73,651 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Leproust Emily M. sold $282,280 worth of shares (2,302 units at $122.62), decreasing direct ownership by 0.30% to 768,427 units (SEC Form 4) (for tax liability)
- Chief Accounting Officer Werner Robert F. sold $29,185 worth of shares (238 units at $122.62), decreasing direct ownership by 0.53% to 44,399 units (SEC Form 4) to satisfy tax liability
- SVP of Human Resources Green Paula sold $111,220 worth of shares (907 units at $122.62), decreasing direct ownership by 0.77% to 117,014 units (SEC Form 4) to satisfy withholding tax